Class Action Against AstraZeneca Dismissed

     MANHATTAN (CN) – A federal judge has dismissed a shareholders’ class action that claims AstraZeneca and four of its officers and board members manipulated the price of its stock. The complaint claimed the company misrepresented the prospects of its heart drug, Exanta, from April 2003 to September 2004.

%d bloggers like this: